fallen by THB 34.73 million, which has led 2nd quarter company’s net profit to fall to THB 0.69 million, a decrease of THB 16.05 million (96.2%). The main factors causing a sharp fall in underwriting
, in order to disclose as the information to the investor and public. Consolidated Operating Results for Quarter 2/2017, the company reported a net profit of Baht 14.82 million, compared to the same
Re: Guidelines Relating to Operating Systems of Fund Management Business
/2561 August 7, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q2/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited
. DOD2019/004 February 20, 2019 Subject: Management’s discussion and analysis of the Company’s operating results for the year 2018 period To: President The Stock Exchange of Thailand DOD Biotech Public
and services increased by 10.87% from last year due to the sharp increment of raw material prices during Quarter 2 to Quarter 3 especially in natural rubber, synthetic rubber and chemicals groups. The
/2561 November 12, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q3/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited
Liabilities 936 914 962 Total Liabilities 956 930 975 Shareholder’s Equity 422 431 432 OPERATING RESULT (MILLION BAHT) Sales Revenue 3,646 3,979 2,021 Gross Profit 229 258 122 Operating Profit 113 131 58 Profit
to lower household income, sharp decline in employment, particularly in export-related manufacturing sectors, and high rate of household debt. Despite the government economic stimulus, the impact of